An analysis of characteristics of subjects examined for incretin effects on pancreatic pathology

Diabetes Technology and Therapeutics

Volumn 15, Issue 8, 2013, Pages 609-618

  Harja, Evis ^a   Lord, Jonathan ^a   Skyler, Jay S ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; GLIPIZIDE; INCRETIN; INSULIN; METFORMIN; SITAGLIPTIN;

ADULT; AGED; AUTOPSY; CLINICAL ARTICLE; DIABETES MELLITUS; FEMALE; HUMAN; MALE; ORGAN DONOR; PANCREAS DISEASE; PANCREAS ISLET CELL HYPERPLASIA; PANCREATITIS; PRIORITY JOURNAL; REVIEW;

ADOLESCENT; ADULT; AGED; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERPLASIA; HYPOGLYCEMIC AGENTS; INCRETINS; MALE; MIDDLE AGED; MODELS, STATISTICAL; PANCREAS; PANCREATITIS; PEPTIDES; PYRAZINES; RECEPTORS, GLUCAGON; TISSUE BANKS; TRIAZOLES; VENOMS; YOUNG ADULT;

EID: 84882254410     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2013.0177     Document Type: Review

References (26)

1. Drucker DJ, Nauck MA: The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-1705
2. Nauck MA: Incretin-based therapies for type 2 diabetes mellitus: Properties, functions, and clinical implications. Am J Med 2011;124(Suppl):S3- S18
3. Patil HR, Al Badarin FJ, Al Shami HA, Bhatti SK, Lavie CJ, Bell DSH, O'Keefe JH: Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus. Am J Cardiol 2012;110:826-833
4. Sun F, Yu K, Wu S, Zhang Y, Yang Z, Shi L, Ji L, Zhan S: Cardiovascular safety and glycemic control of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus: A pairwise and network meta-analysis. Diabetes Res Clin Pract 2012;98:386-395
5. Inzucchi SE, Bergenstal RM, Buse JB, Diamont M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD): Management of hyperglycemia in type 2 diabetes: A patient-centered approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-1379. Erratum in: Diabetes Care 2013;36:490
6. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, Davidson MB, Einhorn D, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez G, Davidson MH: AACE Comprehensive Diabetes Management Algorithm 2013. Endocr Pract 2013;19: 327-336
7. Nauck MA: A critical analysis of the clinical use of incretinbased therapies: Are the GLP-1 therapies safe? The benefits by far outweigh the potential risks. Diabetes Care 2013;36: 2126-2132
8. Gier B, Butler PC: Glucagonlike peptide 1-based drugs and pancreatitis - clarity at last, but what about pancreatic cancer? JAMA Intern Med 2013;173:539-541
9. Butler PC, Elashoff M, Elashoff R, Gale EAM: A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe? How safe are the GLP-1-based therapies? Diabetes Care 2013;36:2118-2125
10. Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC: Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013; 62:2595-2604
11. Kahn SE: Incretin therapy and islet pathology - A time for caution. Diabetes 2013;62:2178-2180
12. Campbell-Thompson M, Wasserfall C, Kaddis J, Albanese- O'Neill A, Staeva T, Nierras C, Moraski J, Rowe P, Gianani R, Eisenbarth G, Crawford J, Schatz D, Pugliese A, Atkinson M: Network for Pancreatic Organ Donors with Diabetes (nPOD): Developing a tissue biobank for type 1 diabetes. Diabetes Metab Res Rev 2012;28:608-617
13. Emery LM, Babu S, Bugawan TL, Norris JM, Erlich HA, Eisenbarth GS, Rewers M: Newborn HLA-DR,DQ genotype screening: Age- and ethnicity-specific type 1 diabetes risk estimates. Pediatr Diabetes 2005;6:136-144
14. Marsh SGE, Albert ED, Bodmer WF, Bontrop RE, Dupont B, Erlich HA, Fernandez-Vina M, Geraghty DE, Holdsworth R, Hurley CK, Lau M, Lee KW, Mach B, Maiers M, Mayr WR, Muller CR, Parham P, Petersdorf EW, Sasazuki T, Strominger JL, Svejgaard A, Terasaki PI, Tiercy JM, Trowsdale J: Nomenclature for factors of the HLA system, 2010. Tissue Antigens 2010;75:291-455
15. Williams AJ, Thrower SL, Sequeiros IM, Ward A, Bickerton AS, Triay JM, Callaway MP, Dayan CM: Pancreatic volume is reduced in adult patients with recently diagnosed type 1 diabetes. J Clin Endocrinol Metab 2012;97: 2109-2113
16. Campbell-Thompson M, Wasserfall C, Montgomery EL, Atkinson MA, Kaddis JS: Pancreas organ weight in individuals with disease-associated autoantibodies at risk for type 1 diabetes. JAMA 2012;308:2337-2339
17. Andrea A: Clinicopathological correlates of pancreatic intraepithelial neoplasia: A comparative analysis of 82 cases with and 152 cases without pancreatic ductal adenocarcinoma. Mod Pathol 2003;16:996-1006
18. Panjwani N, Mulvihill EE, Longuet C, Yusta B, Campbell JE, Brown TJ, Streutker C, Holland D, Cao X, Baggio LL, Drucker DJ: GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE-/- mice. Endocrinology 2013;154:127-139
19. Gelling RW, Du XQ, Dichmann DS, Romer J, Huang H, Cui L, Obici S, Tang B, Holst JJ, Fledelius C, Johansen PB, Rossetti L, Jelicks LA, Serup P, Nishimura E, Charron MJ: Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice. Proc Natl Acad Sci U S A 2003;100:1438-1443
20. Yu R, Dhall D, Nissen NN, Zhou C, Ren SG: Pancreatic neuroendocrine tumors in glucagon receptor-deficient mice. PLoS One 2011;6:e23397
21. Zhou C, Dhall D, Nissen NN, Chen CR, Yu R: Homozygous P86S mutation of the human glucagon receptor is associated with hyperglucagonemia, alpha cell hyperplasia, and islet cell tumor. Pancreas 2009;38:941-946
22. Derosa G, Franzetti IG, Querci F, Carbone A, Ciccarelli L, Piccinni MN, Fogari E, Maffioli P: Exenatide plus metformin compared with metformin alone on b-cell function in patients with type 2 diabetes. Diabet Med 2012; 29:1515-1523
23. Gastaldelli A, Brodows R, D'Alessio D: The effect of chronic twice daily exenatide treatment on b-cell function in new onset type 2 diabetes. Clin Endocrinol (Oxf) March 14 [Epub ahead of print]. doi: 10.1111/cen.12199
24. Mari A, Scherbaum WA, Nilsson PM, Lalanne G, Schweizer A, Dunning BE, Jauffret S, Foley JE: Characterization of the influence of vildagliptin on model-assessed b-cell function in patients with type 2 diabetes and mild hyperglycemia. J Clin Endocrinol Metab 2008;93:103-109
25. American Diabetes Association calls for independent review of incretin therapy. www.diabetes.org/for-media/2013/american-diabetes-association-incretin- therapy.html (accessed July 15, 2013
26. European Medicines Agency: Investigation into GLP-1 based diabetes therapies concluded. www.ema.europa.eu/ema/index.jsp?curl = pages/news-and- events/news/2013/07/news-detail-001856.jsp&mid = WC0b01ac058004d5c1 (accessed July 28, 2013